Burcu Aslan

1.5k total citations
19 papers, 834 citations indexed

About

Burcu Aslan is a scholar working on Molecular Biology, Cancer Research and Genetics. According to data from OpenAlex, Burcu Aslan has authored 19 papers receiving a total of 834 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 11 papers in Cancer Research and 7 papers in Genetics. Recurrent topics in Burcu Aslan's work include Chronic Lymphocytic Leukemia Research (7 papers), MicroRNA in disease regulation (7 papers) and Extracellular vesicles in disease (5 papers). Burcu Aslan is often cited by papers focused on Chronic Lymphocytic Leukemia Research (7 papers), MicroRNA in disease regulation (7 papers) and Extracellular vesicles in disease (5 papers). Burcu Aslan collaborates with scholars based in United States, Türkiye and Egypt. Burcu Aslan's co-authors include Bülent Özpolat, Gabriel Lopez‐Berestein, Anil K. Sood, Cristina Ivan, Pınar Kanlikilicer, George A. Călin, Emine Bayraktar, Recep Bayraktar, Cristian Rodriguez‐Aguayo and Nermin Kahraman and has published in prestigious journals such as Blood, Cancer Research and Clinical Cancer Research.

In The Last Decade

Burcu Aslan

19 papers receiving 829 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Burcu Aslan United States 12 590 395 121 118 89 19 834
Yiping Qu China 17 685 1.2× 314 0.8× 60 0.5× 161 1.4× 60 0.7× 37 1.1k
Michael A. Dengler Germany 14 455 0.8× 143 0.4× 66 0.5× 109 0.9× 49 0.6× 24 706
Byung-Kyu Ryu South Korea 12 510 0.9× 200 0.5× 97 0.8× 210 1.8× 54 0.6× 14 785
Murali K. Ravoori United States 12 455 0.8× 204 0.5× 47 0.4× 198 1.7× 69 0.8× 20 734
Haoyu Ruan China 14 656 1.1× 482 1.2× 69 0.6× 172 1.5× 98 1.1× 22 942
Monica Cojoc Germany 10 487 0.8× 330 0.8× 71 0.6× 434 3.7× 60 0.7× 11 930
Hao‐Xiang Tan China 10 623 1.1× 426 1.1× 75 0.6× 206 1.7× 26 0.3× 12 906
André‐René Blaudszun Germany 7 436 0.7× 245 0.6× 126 1.0× 374 3.2× 46 0.5× 13 799
Meysam Yousefi Iran 18 650 1.1× 232 0.6× 85 0.7× 241 2.0× 31 0.3× 28 1.0k
Weiyuan Wang China 18 530 0.9× 247 0.6× 107 0.9× 213 1.8× 49 0.6× 67 880

Countries citing papers authored by Burcu Aslan

Since Specialization
Citations

This map shows the geographic impact of Burcu Aslan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Burcu Aslan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Burcu Aslan more than expected).

Fields of papers citing papers by Burcu Aslan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Burcu Aslan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Burcu Aslan. The network helps show where Burcu Aslan may publish in the future.

Co-authorship network of co-authors of Burcu Aslan

This figure shows the co-authorship network connecting the top 25 collaborators of Burcu Aslan. A scholar is included among the top collaborators of Burcu Aslan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Burcu Aslan. Burcu Aslan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Aslan, Burcu, et al.. (2024). Transcriptomic and proteomic differences in BTK-WT and BTK-mutated CLL and their changes during therapy with pirtobrutinib. Blood Advances. 8(17). 4487–4501. 1 indexed citations
2.
Aslan, Burcu, Görkem Kısmalı, Ganiraju C. Manyam, et al.. (2022). Pirtobrutinib inhibits wild-type and mutant Bruton’s tyrosine kinase-mediated signaling in chronic lymphocytic leukemia. Blood Cancer Journal. 12(5). 33 indexed citations
3.
Aslan, Burcu, Lisa S. Chen, Philip A. Thompson, et al.. (2022). Pharmacological Profiling of Cells from Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Pirtobrutinib. Blood. 140(Supplement 1). 501–502. 1 indexed citations
4.
Görür, Ayşegül, Recep Bayraktar, Cristina Ivan, et al.. (2021). ncRNA therapy with miRNA-22-3p suppresses the growth of triple-negative breast cancer. Molecular Therapy — Nucleic Acids. 23. 930–943. 36 indexed citations
5.
Aslan, Burcu, Stefan Hübner, Judith A. Fox, et al.. (2021). Vecabrutinib inhibits B-cell receptor signal transduction in chronic lymphocytic leukemia cell types with wild-type or mutant Bruton tyrosine kinase. Haematologica. 107(1). 292–297. 19 indexed citations
6.
Aslan, Burcu, Görkem Kısmalı, Lisa S. Chen, et al.. (2021). Development and characterization of prototypes for in vitro and in vivo mouse models of ibrutinib-resistant CLL. Blood Advances. 5(16). 3134–3146. 6 indexed citations
7.
Sarkar, Aloke, Görkem Kısmalı, Burcu Aslan, et al.. (2020). AMG-176, an Mcl-1 Antagonist, Shows Preclinical Efficacy in Chronic Lymphocytic Leukemia. Clinical Cancer Research. 26(14). 3856–3867. 43 indexed citations
8.
Rodriguez‐Aguayo, Cristian, Emine Bayraktar, Cristina Ivan, et al.. (2019). PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis. EBioMedicine. 40. 290–304. 37 indexed citations
9.
Aslan, Burcu, Mikhila Mahendra, Michael Peoples, et al.. (2019). Abstract 317: Vecabrutinib inhibits C481 mutated Bruton's tyrosine kinase and its downstream signaling in vitro. 317–317. 1 indexed citations
10.
Kanlikilicer, Pınar, Recep Bayraktar, Merve Denizli, et al.. (2018). Exosomal Mirna Confers Chemo Resistance Via Targeting Cav1/p-gp/M2-Type Macrophage Axis in Ovarian Cancer. SSRN Electronic Journal. 2 indexed citations
11.
Kanlikilicer, Pınar, Recep Bayraktar, Merve Denizli, et al.. (2018). Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer. EBioMedicine. 38. 100–112. 185 indexed citations
12.
Rodriguez‐Aguayo, Cristian, Emine Bayraktar, Cristina Ivan, et al.. (2018). PTGER3 Induces Ovary Tumorigenesis and Confers Resistance to Cisplatin Therapy Through Up-Regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 Axis. SSRN Electronic Journal. 3 indexed citations
13.
Denizli, Merve, Burcu Aslan, Lingegowda S. Mangala, et al.. (2017). Chitosan Nanoparticles for miRNA Delivery. Methods in molecular biology. 1632. 219–230. 18 indexed citations
14.
Kanlikilicer, Pınar, Recep Bayraktar, Mohammed H. Rashed, et al.. (2017). Abstract 1988: Exosome-mediated ovarian cancer tumorigenesis mediated by miR1246/Rb/Cav1 axis. Cancer Research. 77(13_Supplement). 1988–1988. 1 indexed citations
15.
Rashed, Mohammed H., Pınar Kanlikilicer, Cristian Rodriguez‐Aguayo, et al.. (2017). Exosomal miR-940 maintains SRC-mediated oncogenic activity in cancer cells: a possible role for exosomal disposal of tumor suppressor miRNAs. Oncotarget. 8(12). 20145–20164. 55 indexed citations
16.
Kanlikilicer, Pınar, Mohammed H. Rashed, Recep Bayraktar, et al.. (2016). Ubiquitous Release of Exosomal Tumor Suppressor miR-6126 from Ovarian Cancer Cells. Cancer Research. 76(24). 7194–7207. 118 indexed citations
17.
Bayraktar, Recep, Martin Pichler, Pınar Kanlikilicer, et al.. (2016). MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase. Oncotarget. 8(7). 11641–11658. 86 indexed citations
18.
González-Villasana, Vianey, Enrique Fuentes‐Mattei, Cristina Ivan, et al.. (2015). Rac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer. Clinical Cancer Research. 21(9). 2127–2137. 63 indexed citations
19.
Aslan, Burcu, Bülent Özpolat, Anil K. Sood, & Gabriel Lopez‐Berestein. (2013). Nanotechnology in cancer therapy. Journal of drug targeting. 21(10). 904–913. 126 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yiping Qu Breakdown of academic impact, for papers by Michael A. Dengler Breakdown of academic impact, for papers by Byung-Kyu Ryu Breakdown of academic impact, for papers by Murali K. Ravoori Breakdown of academic impact, for papers by Haoyu Ruan Breakdown of academic impact, for papers by Monica Cojoc Breakdown of academic impact, for papers by Hao‐Xiang Tan Breakdown of academic impact, for papers by André‐René Blaudszun Breakdown of academic impact, for papers by Meysam Yousefi Breakdown of academic impact, for papers by Weiyuan Wang
Rankless by CCL
2026